NCT06271057View on ClinicalTrials.gov

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

January 15, 2026

Study Completion Date

October 20, 2027

Conditions
Diffuse Large B-cell Lymphoma RefractoryRefractory Primary Mediastinal Large B-Cell LymphomaRefractory Transformed B-cell Non-Hodgkin LymphomaRefractory High Grade B-Cell Lymphoma
Interventions
DRUG

golcadomide

golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166

Trial Locations (13)

13273

RECRUITING

Institut Paoli Calmettes, Marseille

21000

RECRUITING

Chu Dijon Bourgogne, Dijon

31059

RECRUITING

Iuct Oncopole, Toulouse

33604

RECRUITING

Chu de Bordeaux, Pessac

34090

RECRUITING

Chu de Montpellier, Montpellier

35033

RECRUITING

Chu Pontchaillou, Rennes

38700

RECRUITING

Chu de Grenoble, La Tronche

44093

RECRUITING

Chu de Nantes, Nantes

54511

RECRUITING

Chu Brabois, Vandœuvre-lès-Nancy

59037

RECRUITING

Chru de Lille, Lille

75475

RECRUITING

Hopital Saint-Louis, Paris

76038

RECRUITING

Centre Henri Becquerel, Rouen

94010

RECRUITING

Hopital Henri Mondor, Créteil

All Listed Sponsors
collaborator

Lymphoma Study Association

OTHER

lead

The Lymphoma Academic Research Organisation

OTHER